A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children&#39;s Oncology Group study PEPN2111.

CBL0137 - Incuron, Children's Oncology Group

IMC001 - Immunofoco

https://meetings.asco.org/abstracts-presentations/253035/

David Ziegler; Jason Fangusaro; Maria Tsoli; Orazio Vittorio; Tyler Shai-Hee; Charles Minard; Xiaowei Liu; Joel Reid; Nawal Yahya; Jennie Foster; Elizabeth Fox; Brenda Weigel

Apr 23, 2025